カナダ - 英語 - Health Canada

pharmascience inc - loperamide hydrochloride - solution - 0.2mg - loperamide hydrochloride 0.2mg - antidiarrhea agents

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

unit dose services - loperamide hydrochloride (unii: 77ti35393c) (loperamide - unii:6x9oc3h4ii) - loperamide hydrochloride 2 mg

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

mckesson contract packaging - loperamide hydrochloride (unii: 77ti35393c) (loperamide - unii:6x9oc3h4ii) - loperamide hydrochloride 2 mg

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - loperamide hydrochloride (unii: 77ti35393c) (loperamide - unii:6x9oc3h4ii) - loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease. loperamide hydrochloride capsules are also indicated for reducing the volume of discharge from ileostomies. loperamide hydrochloride capsules are contraindicated in patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients. loperamide hydrochloride is contraindicated in patients with abdominal pain in the absence of diarrhea. loperamide hydrochloride is not recommended in infants below 24 months of age. loperamide hydrochloride should not be used as the primary therapy: - in patients with acute dysentery, which is characterized by blood in stools and high fever, - in patients with acute ulcerative colitis, - in patients with bacterial enterocolitis caused by invasive organisms including salmonella, shigella, and campylobacter, - in patients with pseudomembranous colitis associated with the u

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - loperamide hydrochloride (unii: 77ti35393c) (loperamide - unii:6x9oc3h4ii) - loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease. loperamide hydrochloride capsules are also indicated for reducing the volume of discharge from ileostomies. loperamide hydrochloride capsules are contraindicated in patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients. loperamide hydrochloride is contraindicated in patients with abdominal pain in the absence of diarrhea. loperamide hydrochloride is not recommended in infants below 24 months of age. loperamide hydrochloride should not be used as the primary therapy: - in patients with acute dysentery, which is characterized by blood in stools and high fever, - in patients with acute ulcerative colitis, - in patients with bacterial enterocolitis caused by invasive organisms including salmonella, shigella, and campylobacter, - in patients with pseudomembranous colitis associated with the u

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - loperamide hydrochloride - oral capsule - 2mg

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

vantage - loperamide hydrochloride - oral capsule - 2mg

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

ssl international plc - loperamide hydrochloride - oral capsule - 2mg

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

almus pharmaceuticals ltd - loperamide hydrochloride - oral capsule - 2mg

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

tillomed laboratories ltd - loperamide hydrochloride - oral capsule - 2mg